Loading...

Wockhardt Bio

BRSE:WBIO
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WBIO
BRSE
CHF156M
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. CH
    3. ›
  3. Pharmaceuticals & Biotech
Last updated 2019/05/25 21:39
Company description

Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, markets, and exports pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, other European countries, the Middle East, Latin America, and internationally. The last earnings update was 267 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
  • Wockhardt Bio has significant price volatility in the past 3 months.
WBIO Share Price and Events
7 Day Returns
0%
BRSE:WBIO
2.2%
CH Biotechs
0%
CH Market
1 Year Returns
-
BRSE:WBIO
-11.3%
CH Biotechs
3.7%
CH Market
WBIO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Wockhardt Bio (WBIO) 0% 300% - - - -69.4%
CH Biotechs 2.2% 6.6% 24.5% -11.3% 13.4% 49.9%
CH Market 0% -0.4% 1.5% 3.7% 10.6% 10.1%
1 Year Return vs Industry and Market
  • No trading data on WBIO.
  • No trading data on WBIO.
Price Volatility
WBIO
Industry
5yr Volatility vs Market

WBIO Value

 Is Wockhardt Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Wockhardt Bio. This is due to cash flow or dividend data being unavailable. The share price is CHF3.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Wockhardt Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Wockhardt Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BRSE:WBIO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-03-31) in USD $-1.16
BRSE:WBIO Share Price ** BRSE (2019-05-22) in CHF CHF3
BRSE:WBIO Share Price converted to USD reporting currency Exchange rate (CHF/ USD) 0.999 $3
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 21.82x
Switzerland Market PE Ratio Median Figure of 175 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Wockhardt Bio.

BRSE:WBIO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BRSE:WBIO Share Price ÷ EPS (both in USD)

= 3 ÷ -1.16

 -2.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wockhardt Bio is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Wockhardt Bio is loss making, we can't compare the value of its earnings to the Switzerland market.
Price based on expected Growth
Does Wockhardt Bio's expected growth come at a high price?
Raw Data
BRSE:WBIO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts		 Not available
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.3x
Switzerland Market PEG Ratio Median Figure of 125 Publicly-Listed Companies 2.21x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Wockhardt Bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Wockhardt Bio's assets?
Raw Data
BRSE:WBIO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-03-31) in USD $4.88
BRSE:WBIO Share Price * BRSE (2019-05-22) in CHF CHF3
BRSE:WBIO Share Price converted to USD reporting currency Exchange rate (CHF/ USD) 0.999 $3
Switzerland Biotechs Industry PB Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 1.13x
Switzerland Market PB Ratio Median Figure of 212 Publicly-Listed Companies 1.63x
BRSE:WBIO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BRSE:WBIO Share Price ÷ Book Value per Share (both in USD)

= 3 ÷ 4.88

 0.61x

* Primary Listing of Wockhardt Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wockhardt Bio is good value based on assets compared to the CH Biotechs industry average.
X
Value checks
We assess Wockhardt Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
    5. Wockhardt Bio has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

WBIO Future Performance

 How is Wockhardt Bio expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wockhardt Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Wockhardt Bio expected to grow at an attractive rate?
  • Unable to compare Wockhardt Bio's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Wockhardt Bio's earnings growth to the Switzerland market average as no estimate data is available.
  • Unable to compare Wockhardt Bio's revenue growth to the Switzerland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BRSE:WBIO Future Growth Rates Data Sources
Data Point Source Value (per year)
Switzerland Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Switzerland Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 43.5%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 11%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BRSE:WBIO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BRSE:WBIO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-03-31 336 49 -60
2017-03-31 331 3 -45
2016-12-31 349 29 -22
2016-09-30 367 54 2
2016-06-30 393 57 16
2016-03-31 418 59 27
2015-12-31 422 34
2015-09-30 426 2 41
2015-06-30 416 4 34

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Wockhardt Bio is high growth as no earnings estimate data is available.
  • Unable to determine if Wockhardt Bio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BRSE:WBIO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Wockhardt Bio Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BRSE:WBIO Past Financials Data
Date (Data in USD Millions) EPS *
2018-03-31 -1.16
2017-03-31 -0.86
2016-12-31 -0.43
2016-09-30
2016-06-30
2016-03-31 0.54
2015-12-31 0.66
2015-09-30
2015-06-30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Wockhardt Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Wockhardt Bio's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Wockhardt Bio's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Wockhardt Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Wockhardt Bio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

WBIO Past Performance

  How has Wockhardt Bio performed over the past 5 years?

  • Wockhardt Bio's last earnings update was 267 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Wockhardt Bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Wockhardt Bio does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Wockhardt Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Wockhardt Bio's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Wockhardt Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Wockhardt Bio Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BRSE:WBIO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 336.15 -60.46 65.60
2017-03-31 331.11 -44.88 74.03
2016-12-31 349.16 -22.35 72.14
2016-09-30 367.20 2.33 70.24
2016-06-30 392.58 15.65 71.34
2016-03-31 417.95 26.82 72.44
2015-12-31 422.13 34.14 67.66
2015-09-30 426.30 41.46 62.87
2015-06-30 416.29 34.03 56.52
2015-03-31 406.28 26.60 50.17
2014-12-31 452.44 28.24 50.83
2014-09-30 478.46 24.05 49.90
2014-06-30 534.35 59.44 49.69
2014-03-31 590.24 94.82 49.47
2013-12-31 660.76 144.54 49.64
2013-09-30 782.80 225.77 53.30
2013-06-30 789.89 283.86 52.05
2013-03-31 797.75 348.34 50.66

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Wockhardt Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Wockhardt Bio has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Wockhardt Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Wockhardt Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Wockhardt Bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

WBIO Health

 How is Wockhardt Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Wockhardt Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Wockhardt Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Wockhardt Bio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Wockhardt Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Wockhardt Bio Company Filings, last reported 1 year ago.

BRSE:WBIO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 253.63 326.77 178.21
2017-03-31 311.81 323.53 234.50
2016-12-31 311.82 323.53 234.50
2016-09-30 362.60 261.90 191.39
2016-06-30 362.60 261.90 191.39
2016-03-31 397.77 123.02 104.09
2015-12-31 397.77 123.02 104.09
2015-09-30 406.21 190.84 166.42
2015-06-30 406.21 190.84 166.42
2015-03-31 295.73 205.16 134.14
2014-12-31 295.73 205.16 134.14
2014-09-30 281.20 256.47 175.91
2014-06-30 281.20 256.47 175.91
2014-03-31 329.14 300.40 286.32
2013-12-31 329.14 300.40 286.32
2013-09-30 317.28 0.00 226.91
2013-06-30 333.80 0.00 238.72
2013-03-31 263.06 362.35 153.26
  • Wockhardt Bio's level of debt (128.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (135.8% vs 128.8% today).
  • Debt is not well covered by operating cash flow (15.1%, less than 20% of total debt).
  • Unable to confirm if the interest payments on Wockhardt Bio's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Wockhardt Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. Wockhardt Bio has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

WBIO Dividends

 What is Wockhardt Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Wockhardt Bio dividends.
If you bought CHF2,000 of Wockhardt Bio shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Wockhardt Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Wockhardt Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BRSE:WBIO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 166 Stocks 3.1%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 2%
Switzerland Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BRSE:WBIO Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-01-14 0.000 0.000
2016-10-26 0.590 18.131
2015-07-02 0.000 0.000
2014-07-25 1.640 40.648

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Wockhardt Bio has not reported any payouts.
  • Unable to verify if Wockhardt Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Wockhardt Bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Wockhardt Bio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Wockhardt Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Wockhardt Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. Wockhardt Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

WBIO Management

 What is the CEO of Wockhardt Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Wockhardt Bio has no CEO, or we have no data on them.
Management Team

Ajay Sahni

TITLE
Chairman & MD
COMPENSATION
$651K
AGE
52

Pawan Malik

TITLE
VP of Japan & Emerging Markets (formulations) and Global Head of API Business
AGE
43
Board of Directors Tenure

Average tenure of the Wockhardt Bio board of directors in years:

2.3
Average Tenure
  • The average tenure for the Wockhardt Bio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ajay Sahni

TITLE
Chairman & MD
COMPENSATION
$651K
AGE
52

Adrian Ashurst

TITLE
Director
COMPENSATION
$30K
TENURE
12.3 yrs

Sunil Khera

TITLE
Director
AGE
64
TENURE
2.3 yrs

Sirjiwan Singh

TITLE
Director
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Wockhardt Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. Wockhardt Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

WBIO News

Simply Wall St News

Is Wockhardt Bio AG's (BRN:WBIO) Balance Sheet Strong Enough To Weather A Storm?

WBIO’s Debt (And Cash Flows) WBIO has sustained its debt level by about US$327m over the last 12 months – this includes long-term debt. … On top of this, WBIO has produced cash from operations of US$49m over the same time period, resulting in an operating cash to total debt ratio of 15%, meaning that WBIO’s current level of operating cash is not high enough to cover debt. … Looking at WBIO’s US$260m in current liabilities, the company has maintained a safe level of current assets to meet its obligations, with the current ratio last standing at 1.8x.

Simply Wall St - –

WBIO Company Info

Description

Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, markets, and exports pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, other European countries, the Middle East, Latin America, and internationally. The company’s products cover various therapeutic categories, including central nervous system agents, hormones and related agents, cardiovascular agents, anti-infective agents, and respiratory agents, as well as other agents, such as gastrointestinal, dermatological, and biological (vaccines) agents. The company is based in Zug, Switzerland. Wockhardt Bio AG is a subsidiary of Wockhardt Limited.

Details
Name: Wockhardt Bio AG
WBIO
Exchange: BRSE
Founded:
CHF155,844,000
51,948,000
Website: http://www.wockhardtbio.com
Address: Wockhardt Bio AG
Grafenauweg 6,
Zug,
Zug, 6300,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BRSE WBIO Bearer Shares Berne Stock Exchange CH CHF 19. Dec 2013
Number of employees
Current staff
Staff numbers
0
Wockhardt Bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 21:39
End of day share price update: 2019/05/22 00:00
Last earnings filing: 2018/08/31
Last earnings reported: 2018/03/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)